Furthermore, previous randomized double-blind placebo-controlled study38, which investigated the effect of telmisartan on PPAR-γ target genes CD36 and CD163 in patients with metabolic syndrome, showed that the activation of PPAR-γ target gene was not demonstrated by telmisartan at 80 mg (the highest dose used in our study) and partial activation of PPAR-γ target gene was observed only in 160 mg of telmisartan. Here, CD163 is linked to metabolic syndrome.